Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that new data on mitapivat, an oral pyruvate… read more.
Exicure, Inc, a clinical-stage biotechnology company developing therapeutics for hematologic diseases announced that results from its completed Phase 2 study evaluating burixafor, a small molecule CXCR4 antagonist, will… read more.
Rigel Pharmaceuticals, Inc. a commercial stage biotechnology company focused on hematologic disorders and cancer, announced that data from the ongoing Phase 1b study of R2891, a potent and… read more.
Genmab A/S announced that more than 20 abstracts evaluating epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, across lines of therapy and B-cell non-Hodgkin’s lymphoma (NHL) subtypes, will… read more.
GERPAC Congress highlights The use of licensed ready-to-use (RTU) gemcitabine in polypropylene infusion bags (Sun Pharma) is associated with fewer carbon emissions than in-house compounding from glass vials,… read more.
Genentech, a member of the Roche Group announced that it will showcase 46 abstracts, including 12 oral presentations, from its industry-leading hematology portfolio at the 67th American Society… read more.
Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present new and updated data for CAR T-cell therapy candidate, GLPG51011, at the 67th American Society of… read more.
GERPAC Congress highlights A near-infrared (NIR) spectroscopic method for analytical checks of compounded anti-cancer drugs could replace the current double visual checks in future, according Julie Evrard (Groupe… read more.
Teva Pharmaceutical Industries Ltd. entered into a license agreement with Prestige Biopharma, for the commercialization of Tuznue (trastuzumab), a biosimilar to Herceptin, across a majority of European markets…. read more.
Women living in parts of the United States with lower air quality, especially neighborhoods with heavy emissions from motor vehicles, are more likely to develop breast cancer, according… read more.
Pfizer Inc and Astellas announced final overall survival (OS) results from the Phase III EMBARK study evaluating Xtandi (enzalutamide), in combination with leuprolide and as monotherapy, in men with… read more.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for Breyanzi. The marketing authorisation… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
